Social support Social Network Interview · schizophrenia
Technology‐mediated psychoeducation led to lower social support Social Network Interview compared with standard care intervention; GRADE not reported.
1 finding from 1 review
Compliance/satisfaction: medication ‐ not compliant ‐ long‐term · schizophrenia
It is very uncertain whether technology‐mediated psychoeducation + standard care intervention changes compliance/satisfaction: medication ‐ not compliant ‐ long‐term compared with standard care intervention (very low certainty).
1 finding from 1 review
Clinical response: no clinically significant response in mental state · schizophrenia
Technology‐mediated psychoeducation + standard care intervention showed no clear difference in mental state: not improved ‐ short‐term BPRS compared with standard care intervention (low certainty).
1 finding from 1 review
Intervention not reported
Global effect: 1a. Medium‐term ‐ Average end point score on various outcomes ‐ CGI‐severity (low = favourable) ( · schizophrenia
1 finding from 1 review
Intervention not reported
Leaving the study early ‐ Adverse event: Short‐term · schizophrenia
The intervention showed no clear difference in leaving the study early ‐ Adverse event: Short‐term; GRADE not reported.
1 finding from 1 review
Intervention not reported
Mental state: 1b. Average end point score on various outcomes‐PANSS (medium‐term) ‐ Medium‐term ‐ PANSS negative end point score (low = favourable) · schizophrenia
1 finding from 1 review
Intervention not reported
Mental state: 1b.Average end point score on various outcomes‐PANSS (medium‐term) ‐ Medium term ‐ PANSS general psychopathology end point score (low = favourable) · schizophrenia
1 finding from 1 review
Intervention not reported
Cognitive function: 3. Short‐term ‐ Average end point score on various subscales of WAIS III (high = favourable) ‐ Digit symbol score · schizophrenia
1 finding from 1 review
Intervention not reported
Cognitive function: 4. Short‐term ‐ Average end point score on various subscales of HVLT (high = favourable) ‐ Recognition · schizophrenia
1 finding from 1 review
Intervention not reported
Adverse event: 11a. Short‐term ‐ Average end point score on EPSEs scale (low = favourable) ‐ AIMS · schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
Paliperidone palmitate leads to lower leaving the study early ‐ any reason Reported by trial author compared with placebo (high certainty).
1 finding from 1 review
Death by end of trial · patients with schizophrenia
Paliperidone palmitate showed no clear difference in death Reported by trial author compared with risperidone long‐acting injection (low certainty).
1 finding from 1 review
No clinically important change Number of people whose PANSS score either increased or did not decrease by at least 30% from the beginning to the end of the trial · patients with schizophrenia
Paliperidone palmitate showed no clear difference in no clinically important change Number of people whose PANSS score… compared with risperidone long‐acting injection (low certainty).
1 finding from 1 review
Relapse: recurrence of psychotic symptoms Reported by trial author as adverse event · patients with schizophrenia
Paliperidone palmitate showed no clear difference in relapse: recurrence of psychotic symptoms Reported by trial authors… compared with risperidone long‐acting injection (moderate certainty).
1 finding from 1 review
Cost ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health related quality of life ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No clinically important change Number of people whose PANSS score either increased or did not decrease by at least 30% from the beginning to the end of the trial · patients with schizophrenia
Paliperidone palmitate probably leads to lower no clinically important change Number of people whose PANSS score… compared with placebo (moderate certainty).
1 finding from 1 review
Relapse: recurrence of psychotic symptoms Reported by trial author as adverse event · patients with schizophrenia
Paliperidone palmitate probably leads to lower relapse: recurrence of psychotic symptoms Reported by trial author… compared with placebo (moderate certainty).
1 finding from 1 review
Average change in prolactin in men Serum prolactin level (ng/mL) · patients with schizophrenia
1 finding from 1 review
Average change in prolactin in women Serum prolactin level (ng/mL) · patients with schizophrenia
1 finding from 1 review